Attorneys for three cancer patients told a Missouri jury that Bayer’s Monsanto unit failed to adequately test Roundup before selling it, opening a trial that could indicate how courts handle design-defect and other claims not centered on cancer-warning labels. Bayer faces approximately 65,000 U.S. state and federal claims from people who say they developed cancer after using the weedkiller. The company is pursuing a $7.25 billion class-action settlement covering nearly all existing and future claims, which is under review by a Missouri state court judge in St. Louis. The trial involves Theresa Aretino, Cynthia Fernandez and Betty Larkin, who regularly used Roundup and later developed non-Hodgkin lymphoma; Fernandez died before the trial began. Bayer denies the allegations and says decades of studies show glyphosate, Roundup’s active ingredient, is safe and does not cause cancer. The case follows a June U.S. Supreme Court ruling that barred lawsuits focused on allegedly inadequate cancer warnings because federal law requires herbicide makers to use labels approved by the U.S. Environmental Protection Agency, or EPA. The EPA is reassessing glyphosate and estimates it will complete the review by the end of 2026.